283 related articles for article (PubMed ID: 33125154)
1. Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.
Huang T; Luo X; Wu B; Peng P; Dai Y; Hu G; Qiu H; Yuan X
Oncol Rep; 2020 Dec; 44(6):2634-2644. PubMed ID: 33125154
[TBL] [Abstract][Full Text] [Related]
2. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
[TBL] [Abstract][Full Text] [Related]
3. Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways.
Su B; Huang T; Jin Y; Yin H; Qiu H; Yuan X
Gastric Cancer; 2021 Mar; 24(2):352-367. PubMed ID: 33030616
[TBL] [Abstract][Full Text] [Related]
4. Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib.
Lian X; Zhu C; Lin H; Gao Z; Li G; Zhang N; Cao B; Kang Y
Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32022229
[TBL] [Abstract][Full Text] [Related]
5. Pyrotinib treatment enhances the radiosensitivity in HER2-positive brain metastatic breast cancer patients.
Tian W; Hao S; Wang L; Chen Y; Li Z; Luo D
Anticancer Drugs; 2022 Jan; 33(1):e622-e627. PubMed ID: 34407046
[TBL] [Abstract][Full Text] [Related]
6. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract][Full Text] [Related]
7. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.
Li X; Yang C; Wan H; Zhang G; Feng J; Zhang L; Chen X; Zhong D; Lou L; Tao W; Zhang L
Eur J Pharm Sci; 2017 Dec; 110():51-61. PubMed ID: 28115222
[TBL] [Abstract][Full Text] [Related]
8. Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2
Yi J; Chen S; Yi P; Luo J; Fang M; Du Y; Zou L; Fan P
Oncol Res; 2020 Dec; 28(5):519-531. PubMed ID: 32727638
[TBL] [Abstract][Full Text] [Related]
9. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
[TBL] [Abstract][Full Text] [Related]
10. Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer.
Niu Q; Liu J; Huang T; Su B; Zhang Y; Yuan X
Oncol Res Treat; 2023; 46(1-2):11-25. PubMed ID: 36481773
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
[TBL] [Abstract][Full Text] [Related]
12. Pyrotinib in combination with first-line trastuzumab and docetaxel for patients with HER2-positive metastatic breast cancer: a new therapeutic option?
Berton Giachetti PPM; Curigliano G
Nat Rev Clin Oncol; 2024 Mar; 21(3):171-172. PubMed ID: 38114789
[No Abstract] [Full Text] [Related]
13. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
[TBL] [Abstract][Full Text] [Related]
14. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
[TBL] [Abstract][Full Text] [Related]
15. Pyrotinib alone or in combination with docetaxel in refractory HER2-positive gastric cancer: A dose-escalation phase I study.
Liu D; Kou F; Gong J; Wang Z; Zhang X; Li J; Li Y; Li J; Zhou J; Lu M; Wang X; Lu Z; Cao Y; Zou J; Zhu X; Xu R; Shen L
Cancer Med; 2023 May; 12(9):10704-10714. PubMed ID: 37081722
[TBL] [Abstract][Full Text] [Related]
16. Pyrotinib-based therapeutic approaches for HER2-positive breast cancer: the time is now.
Qi X; Shi Q; Xuhong J; Zhang Y; Jiang J
Breast Cancer Res; 2023 Oct; 25(1):113. PubMed ID: 37789330
[TBL] [Abstract][Full Text] [Related]
17. Pyrotinib in the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: A case report.
Dai J; Chen Y; Tang C; Wei X; Gong Y; Wei J; Gu D; Chen J
Medicine (Baltimore); 2020 Jun; 99(25):e20809. PubMed ID: 32569228
[TBL] [Abstract][Full Text] [Related]
18. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
Zhu W; Wu J; Cui M; Zhang L
Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
[TBL] [Abstract][Full Text] [Related]
19. Pyrotinib: First Global Approval.
Blair HA
Drugs; 2018 Nov; 78(16):1751-1755. PubMed ID: 30341682
[TBL] [Abstract][Full Text] [Related]
20. Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial.
Wang C; Lin Y; Zhou Y; Mao F; Zhu H; Guan J; Zhang X; Shen S; Huang X; Chen C; Yao R; Zhao J; Sun Q
BMC Cancer; 2020 Jul; 20(1):653. PubMed ID: 32660609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]